Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: ibrahimi n. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. Nat Commun. 2022. PMID: 36071033 Free PMC article.
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: ibrahimi n. Nat Commun. 2022 Nov 14;13(1):6928. doi: 10.1038/s41467-022-34580-3. Nat Commun. 2022. PMID: 36376284 Free PMC article. No abstract available.
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.
Chapuis N, Ibrahimi N, Belmondo T, Goulvestre C, Berger AE, Mariaggi AA, Andrieu M, Chenevier-Gobeaux C, Bayle A, Campos L, Cheurfa C, Chocron R, Diehl JL, Doumenc B, Duchemin J, Duprat M, François F, Gendron N, Mirault T, Pène F, Philippe A, Pommeret F, Sanchez O, Smadja DM, Szwebel TA, Silvin A, Ginhoux F, Lacroix L, Jules-Clément G, Rapeteramana S, Mavier C, Steller L, Perniconi B, André F, Drubay D, Fontenay M, Hüe S, Paul S, Solary E. Chapuis N, et al. Among authors: ibrahimi n. EBioMedicine. 2022 Jun;80:104077. doi: 10.1016/j.ebiom.2022.104077. Epub 2022 May 26. EBioMedicine. 2022. PMID: 35644124 Free PMC article.
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study.
Plais H, Labruyère M, Creutin T, Nay P, Plantefeve G, Tapponnier R, Jonas M, Ngapmen NT, Le Guennec L, De Roquetaillade C, Argaud L, Jamme M, Goulenok C, Merouani K, Leclerc M, Sauneuf B, Shidasp S, Stoclin A, Bardet A, Mir O, Ibrahimi N, Llitjos JF. Plais H, et al. Among authors: ibrahimi n. Front Oncol. 2022 Mar 10;12:858276. doi: 10.3389/fonc.2022.858276. eCollection 2022. Front Oncol. 2022. PMID: 35359407 Free PMC article.
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study.
Charles C, Bardet A, Ibrahimi N, Aromatario O, Cambon L, Imbert A, Pons M, Raynard B, Sauveplane D, Pouchepadass C, Baudinet C, Lambotte O, Marabelle A, Dauchy S. Charles C, et al. Among authors: ibrahimi n. J Telemed Telecare. 2023 Oct;29(9):716-724. doi: 10.1177/1357633X211021743. Epub 2021 Jun 17. J Telemed Telecare. 2023. PMID: 34137641